Our submission on the call for evidence on the new Strategy for European Life Sciences can be found here.

EFPIA welcomes the Commission initiative to develop a robust EU Life Sciences Strategy to strengthen Europe competitiveness and close the innovation gap with global peers.

The strategy must address challenges across the full value chain, deepen public-private collaboration, and reinforce the link between a thriving industry, world-class research and manufacturing, and equitable access to medicines. 

Learn more here.

CEOs of the research-based pharmaceutical industry issued a stark warning to President von der Leyen that unless Europe delivers rapid, radical policy change then pharmaceutical research, development and manufacturing is increasingly likely to be directed towards the US.

Read more here.

A significant step forward in addressing the leading cause of death in Europe is set to take place with the official launch of the MEP Cardiovascular Health Group in the European Parliament.

Chaired by MEP Romana Jerković (S&D, Croatia), this cross-party group is poised to place prevention and tackling of cardiovascular disease (CVD) at the forefront of the EU’s health agenda.

Learn more here.

Elevated lipoprotein (a) levels are a risk factor for cardiovascular disease. New therapies can reduce the amount of lipoprotein (a) and reduce its associated risks.

Imagine how many strokes and heart attacks could be prevented.

Discover more in our pipeline review.